BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, November 23, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» OR-641 promotes antitumoral responses through LILRB1/LILRB2 dual targeting
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
OR-641 promotes antitumoral responses through LILRB1/LILRB2 dual targeting
Nov. 17, 2023
No Comments
Oncoresponse Inc. has presented preclinical data on OR-641 as a potential immunotherapeutic for cancer.
BioWorld Science
Conferences
Society for Immunotherapy of Cancer
Cancer
Immuno-oncology
